Free Trial

Maridea Wealth Management LLC Invests $202,000 in Harrow, Inc. $HROW

Harrow logo with Medical background

Key Points

  • Maridea Wealth Management LLC invested $202,000 in Harrow, Inc., acquiring 6,615 shares during the second quarter.
  • Harrow's stock has recently **increased by 2.1%**, currently trading at $47.10, with institutional investors owning **72.76%** of the company's stock.
  • Harrow reported $0.24 earnings per share in the latest quarter, significantly beating analyst expectations, and has received several **buy ratings** from analysts with an average target price of $65.33.
  • MarketBeat previews the top five stocks to own by October 1st.

Maridea Wealth Management LLC purchased a new position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 6,615 shares of the company's stock, valued at approximately $202,000.

A number of other hedge funds also recently modified their holdings of the business. SJS Investment Consulting Inc. raised its position in shares of Harrow by 97.6% during the second quarter. SJS Investment Consulting Inc. now owns 6,073 shares of the company's stock worth $185,000 after purchasing an additional 3,000 shares during the period. Voya Investment Management LLC raised its position in Harrow by 4,035.5% in the 1st quarter. Voya Investment Management LLC now owns 381,461 shares of the company's stock valued at $10,147,000 after buying an additional 372,237 shares during the last quarter. Rhumbline Advisers raised its position in Harrow by 7.2% in the 1st quarter. Rhumbline Advisers now owns 42,975 shares of the company's stock valued at $1,143,000 after buying an additional 2,879 shares during the last quarter. Strs Ohio acquired a new stake in Harrow in the 1st quarter valued at approximately $149,000. Finally, Dynamic Technology Lab Private Ltd raised its position in Harrow by 34.7% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 16,908 shares of the company's stock valued at $450,000 after buying an additional 4,358 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Stock Up 2.1%

HROW stock opened at $47.10 on Friday. The company has a quick ratio of 0.58, a current ratio of 0.62 and a debt-to-equity ratio of 0.78. The business has a 50 day moving average price of $38.47 and a two-hundred day moving average price of $31.37. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -188.40 and a beta of 0.33. Harrow, Inc. has a twelve month low of $20.85 and a twelve month high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.01 by $0.23. The firm had revenue of $63.74 million during the quarter, compared to the consensus estimate of $64.23 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. Harrow has set its FY 2025 guidance at EPS. Analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. BTIG Research reissued a "buy" rating and issued a $63.00 target price on shares of Harrow in a research report on Wednesday. B. Riley lifted their target price on Harrow from $65.00 to $70.00 and gave the company a "buy" rating in a research report on Tuesday. HC Wainwright lifted their target price on Harrow from $60.00 to $64.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. William Blair assumed coverage on Harrow in a research report on Tuesday, June 10th. They issued an "outperform" rating on the stock. Finally, Craig Hallum lifted their target price on Harrow from $54.00 to $64.00 and gave the company a "buy" rating in a research report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Harrow presently has a consensus rating of "Moderate Buy" and an average target price of $65.33.

Get Our Latest Stock Analysis on Harrow

About Harrow

(Free Report)

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Read More

Institutional Ownership by Quarter for Harrow (NASDAQ:HROW)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Harrow Right Now?

Before you consider Harrow, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.

While Harrow currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.